Neuvivo

👥 7 employees💰 Last funded Dec 2021
Biotechnology🌐 neuvivo.com
Website LinkedIn
Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Neuvivo?
Neuvivo has 2 investors on record on gritt.io.
When did Neuvivo last raise funding?
The most recent investment in Neuvivo recorded on gritt.io was in December 2021.
What industry is Neuvivo in?
Neuvivo operates in Biotechnology. Find similar Biotechnology investors on gritt.io.